Lifotronic(688389)2024-05-28 10:34Financial Performance - In Q1 2024, the company achieved operating revenue of ¥305,741,862.07, representing a year-on-year growth of 10.06% [2] - The net profit attributable to shareholders was ¥107,218,856.40, with a year-on-year increase of 21.69% [2] - The net profit after deducting non-recurring gains and losses was ¥103,288,918.11, reflecting a growth of 24.60% [2] - Operating cash flow for the period was ¥26,082,118.62, up by 12.51% year-on-year [2] Business Segments - The main revenue sources in Q1 2024 were from the in vitro diagnostics and treatment & rehabilitation sectors, with total revenue of ¥306 million and net profit of ¥107 million [3] - In vitro diagnostics generated revenue of ¥242 million, while treatment & rehabilitation contributed ¥60 million [3] Product Development and Market Position - The company offers three main categories of skin aesthetic products: basic photonic products, specialty energy products, and aesthetic consumables [3] - The company aims to enhance existing products and develop new technologies to maintain a competitive edge in the domestic skin aesthetic market [3] - The aesthetic market remains vibrant, with positive client feedback on the company's products [3] Investor Relations - The investor relations activity involved 26 institutions and 30 participants, held via phone conference and at the company headquarters [2] - The meetings took place on May 23, 24, 27, and 28, 2024 [2]